Copyright
©The Author(s) 2019.
World J Gastroenterol. Mar 21, 2019; 25(11): 1327-1340
Published online Mar 21, 2019. doi: 10.3748/wjg.v25.i11.1327
Published online Mar 21, 2019. doi: 10.3748/wjg.v25.i11.1327
Figure 4 Estimated cumulative costs of base case and hepatitis C virus elimination scenarios in 2030 and 2035.
A: Direct costs; B: Indirect/societal costs; C: Total costs. HCV: Hepatitis C virus.
- Citation: Gountas I, Sypsa V, Papatheodoridis G, Souliotis K, Athanasakis K, Razavi H, Hatzakis A. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. World J Gastroenterol 2019; 25(11): 1327-1340
- URL: https://www.wjgnet.com/1007-9327/full/v25/i11/1327.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i11.1327